WO2024015803A3 - Encrypted rna and methods of its use - Google Patents
Encrypted rna and methods of its use Download PDFInfo
- Publication number
- WO2024015803A3 WO2024015803A3 PCT/US2023/069976 US2023069976W WO2024015803A3 WO 2024015803 A3 WO2024015803 A3 WO 2024015803A3 US 2023069976 W US2023069976 W US 2023069976W WO 2024015803 A3 WO2024015803 A3 WO 2024015803A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- encrypted
- methods
- rna
- rnas
- polypeptides
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Abstract
Provided herein are encrypted RNAs, and DNAs that encode encrypted RNAs, that enable increased translation of polypeptides, including therapeutic polypeptides, after being contacted by translation activators, and methods of their use.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263388110P | 2022-07-11 | 2022-07-11 | |
US63/388,110 | 2022-07-11 | ||
US202263390139P | 2022-07-18 | 2022-07-18 | |
US202263390245P | 2022-07-18 | 2022-07-18 | |
US63/390,139 | 2022-07-18 | ||
US63/390,245 | 2022-07-18 | ||
US202363493906P | 2023-04-03 | 2023-04-03 | |
US63/493,906 | 2023-04-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024015803A2 WO2024015803A2 (en) | 2024-01-18 |
WO2024015803A3 true WO2024015803A3 (en) | 2024-02-22 |
Family
ID=87567164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/069976 WO2024015803A2 (en) | 2022-07-11 | 2023-07-11 | Encrypted rna and methods of its use |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024015803A2 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000015853A1 (en) * | 1998-09-14 | 2000-03-23 | Mount Sinai School Of Medicine Of The City, University Of New York | Recombinant newcastle disease virus rna expression systems and vaccines |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104356236B (en) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | Human monoclonal antibodies to programmed death ligand 1(PD-L1) |
EP2133365B1 (en) | 2006-12-27 | 2017-05-17 | Emory University | Compositions and methods for the treatment of infections and tumors |
EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
PE20120341A1 (en) | 2008-12-09 | 2012-04-24 | Genentech Inc | ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION |
WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
AU2013201121A1 (en) | 2011-09-20 | 2013-04-04 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
EP2822957A1 (en) | 2012-03-07 | 2015-01-14 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
CU20170052A7 (en) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | ANTIBODY MOLECULES THAT JOIN PD-L1 |
-
2023
- 2023-07-11 WO PCT/US2023/069976 patent/WO2024015803A2/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000015853A1 (en) * | 1998-09-14 | 2000-03-23 | Mount Sinai School Of Medicine Of The City, University Of New York | Recombinant newcastle disease virus rna expression systems and vaccines |
Non-Patent Citations (2)
Title |
---|
THIEL V ET AL: "Multigene RNA Vector Based on Coronavirus Transcription", JOURNAL OF VIROLOGY, vol. 77, no. 18, 15 September 2003 (2003-09-15), US, pages 9790 - 9798, XP055229181, ISSN: 0022-538X, DOI: 10.1128/JVI.77.18.9790-9798.2003 * |
ZHANG J ET AL: "Exploiting cis-acting replication elements to direct hepatitis C virus-dependent transgene expression", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 79, no. 10, 1 May 2005 (2005-05-01), pages 5923 - 5932, XP002420659, ISSN: 0022-538X, DOI: 10.1128/JVI.79.10.5923-5932.2005 * |
Also Published As
Publication number | Publication date |
---|---|
WO2024015803A2 (en) | 2024-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020096988A3 (en) | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy | |
AU2018372763A1 (en) | Materials and methods for treatment of autosomal dominant Retinitis Pigmentosa | |
WO2020096631A3 (en) | Compositions, methods and systems for protein corona analysis and uses thereof | |
WO2008098104A8 (en) | Inhibitors of akt activity | |
CO2020014729A2 (en) | Gene therapy constructs and methods for their use | |
MXPA06001134A (en) | INHIBITORS OF Akt ACTIVITY. | |
UA91032C2 (en) | Formulations comprising ecteinascidin and a disaccharide | |
CR20220317A (en) | Anti-cd73 antibodies and uses thereof | |
CA3139195A1 (en) | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | |
BR112022010179A2 (en) | YELLOW FEVER ANTI-VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE | |
WO2009158371A8 (en) | Inhibitors of akt activity | |
EP1712243A4 (en) | Gene therapy for tumor using minus-strand rna viral vectors encoding immunostimulatory cytokines | |
WO2018140887A8 (en) | Method for reducing bioburden in chromatography | |
WO2009158374A3 (en) | Inhibitors of akt activity | |
WO2019241672A3 (en) | Glycosylated comp pilin variants, methods of making and uses thereof | |
WO2020070678A3 (en) | Antibodies specific for human and cynomolgus apoc3 and methods of use thereof | |
TW200507840A (en) | Method of treating multiple myeloma | |
WO2021242793A3 (en) | Nucleic acid artificial mini-proteome libraries | |
WO2024015803A3 (en) | Encrypted rna and methods of its use | |
IL141984A0 (en) | Akt nucleic acids, polypeptides, and uses thereof | |
WO2022009052A3 (en) | Prostate neoantigens and their uses | |
WO2021216876A3 (en) | Antibodies to coronavirus spike protein and methods of use thereof | |
BR112022021918A2 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | |
WO2020260898A3 (en) | Novel cancer antigens and methods | |
EP4011310A4 (en) | Probe application mode switching system and method, and tumor therapy instrument |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23752124 Country of ref document: EP Kind code of ref document: A2 |